[1] JOHAL M, LEVIN A. Vitamin D and parathyroid hormone in general populations: understandings in 2009 and applications to chronic kidney disease [J]. Clinical journal of the American Society of Nephrology : CJASN, 2009, 4(9): 1508-14.[2] NAVES-DIAZ M, PASSLICK-DEETJEN J, GUINSBURG A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study [J]. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, 26(6): 1938-47.[3] LAU W L, OBI Y A-O, KALANTAR-ZADEH K A-O. Parathyroidectomy in the Management of Secondary Hyperparathyroidism [J]. Clin J Am Soc Nephrol. 2018, 13(6):952-961. [4] MALBERTI F, MARCELLI D FAU - CONTE F, CONTE F FAU - LIMIDO A, et al. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study [J]. J Am Soc Nephrol. 2001, 12(6):1242-8. [5] IVARSSON K M, AKABERI S, ISAKSSON E, et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism [J]. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, 30(12): 2027-33.[6] Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59 [J]. Kidney international supplements, 2017, 7(3): e1.[7] 国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要 [J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 52-7.[8] PAVLOVIC D, TOMIC BRZAC H. Ultrasonographic evaluation of parathyroid hyperplasia in dialysis patients [J]. Scientific World Journal. 2006, 6:1599-608. [9] SILVER J, KILAV R FAU - NAVEH-MANY T, NAVEH-MANY T. Mechanisms of secondary hyperparathyroidism [J]. Am J Physiol Renal Physiol. 2002, 283(3):F367-76. [10] CUNNINGHAM J, LOCATELLI F FAU - RODRIGUEZ M, RODRIGUEZ M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options [J]. Clin J Am Soc Nephrol. 2011, 6(4):913-21.[11] INABA M, OKUNO S FAU - CHOU H, CHOU H FAU - IMANISHI Y, et al. Positive correlation of serum bio-intact PTH(1-84) but not intact PTH with parathyroid gland size in hemodialysis patients [J]. Biomed Pharmacother. 2006, 60(2):62-5.[12] FANG L, TANG B, HOU D, et al. Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism [J]. BMC Nephrol. 2015, 16:82. [13] 王继伟, 张兵林, 张凌. 甲状旁腺激素与尿毒症继发甲状旁腺功能亢进术后病理的相关性研究 [J]. 中国血液净化, 2015, 14(12): 732-5.[14] LEONG D C W, LO J, NGUYEN H, et al. The correlation of preoperative biochemical tests with parathyroid adenoma weight. Can we predict expected adenoma weight preoperatively? [J]. Asian J Surg. 2019, S1015-9584(19)30822-X. [15] SOUBERBIELLE J C, BOUTTEN A FAU - CARLIER M C, CARLIER MC FAU - CHEVENNE D, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients [J]. Kidney Int. 2006, 70(2):345-50. [16] HOCHER B, ARMBRUSTER FP FAU - STOEVA S, STOEVA S FAU - REICHETZEDER C, et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress--do we need a fourth generation parathyroid hormone assay? [J]. PLoS One. 2012, 7(7):e40242. [17] HOCHER B, OBERTHUR D FAU - SLOWINSKI T, SLOWINSKI T FAU - QUERFELD U, et al. Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients [J]. Kidney Blood Press Res. 2013, 37(4-5):240-51.[18] CAVALIER E, SOUBERBIELLE J C, DELANAYE P. PTH determination in hemodialyzed patients-A laboratory perspective [J]. Semin Dial. 2019, 32(6):490-492.[19] HOCHER B, ZENG S. Need for better PTH assays for clinical research and patient treatment [J]. Clin Chem Lab Med. 2018, 56(2):183-185.[20] LEWIN E, OLGAARD K. Influence of parathyroid mass on the regulation of PTH secretion [J]. Kidney Int Suppl. 2006, 102:S16-21.[21] TOMINAGA Y, TANAKA Y, SATO K, et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism [J]. Seminars in surgical oncology, 1997, 13(2): 78-86.[22] TOMINAGA Y, NUMANO M FAU - TANAKA Y, TANAKA Y FAU - UCHIDA K, et al. Surgical treatment of renal hyperparathyroidism [J]. Semin Surg Oncol. 1997, 13(2):87-96.[23] FUKAGAWA M, YOKOYAMA K, KOIWA F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder [J]. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2013, 17(3): 247-88. |